We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NRXBF market cap is 26.66M. The company's latest EPS is USD -0.0754 and P/E is -10.21.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26k | -15k | -24k | -4.43M | -3.51M |
| Net Income | -85k | -27k | -166k | -8.17M | -3.64M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | USD ($) | USD ($) | |
| Total Assets | 35k | 18k | 2.13M | 2.79M | 2.17M |
| Total Liabilities | 91k | 101k | 2.38M | 698k | 1.98M |
| Total Equity | -56k | -83k | -249k | 2.1M | 189k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | USD ($) | USD ($) | |
| Operating | -127k | -1,000 | -96k | -3.85M | -2.94M |
| Investing | N/A | N/A | -2.12M | -89k | -97k |
| Financing | 91k | 8k | 2.21M | 4.3M | 1.13M |
| Market Cap | 26.66M |
| Price to Earnings Ratio | -10.21 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 68.75 |
| Price to Book Ratio | 196.57 |
| Dividend Yield | - |
| Shares Outstanding | 48.25M |
| Average Volume (1 week) | 10.55k |
| Average Volume (1 Month) | 14.59k |
| 52 Week Change | 138.19% |
| 52 Week High | 0.8828 |
| 52 Week Low | 0.2197 |
| Spread (Intraday) | 0.02 (4.22%) |
| Company Name | NurExone Biologic Inc (QB) |
| Address |
suite 1600, 1 first canadian place, 100 king street toronto, ontario M5X 1G5 |
| Website | https://www.nurexone.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
